MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Published in:

Hematological Oncology, 2023, v. 41, p. 239, doi. 10.1002/hon.3163_156

By:

• Kater, A. P.;
• Harrup, R.;
• Kipps, T. J.;
• Eichhorst, B.;
• Owen, C. J.;
• Assouline, S.;
• Lamanna, N.;
• Robak, T.;
• Serna, J. d. l.;
• Jaeger, U.;
• Cartron, G.;
• Montillo, M.;
• Mellink, C.;
• Chyla, B.;
• Thadani‐Mulero, M.;
• Lefebure, M.;
• Jiang, Y.;
• Millen, R.;
• Boyer, M.;
• Seymour, J. F.

Publication type:

Article